Enanta Pharmaceuticals Inc (ENTA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of 1.28. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 15.12 to 31.56 according to relative valuation method. Compared to the current price of 14.51 USD , Enanta Pharmaceuticals Inc By Undervalued By 4.04%.

Relative Value

Fair Zone

15.12-31.56

Current Price：14.51

4.04%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Enanta Pharmaceuticals Inc (ENTA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Enanta Pharmaceuticals Inc (ENTA) has a current Price-to-Book (P/B) ratio of 4.77. Compared to its 3-year average P/B ratio of 1.85, the current P/B ratio is approximately 158.27% higher. Relative to its 5-year average P/B ratio of 2.37, the current P/B ratio is about 100.96% higher. Enanta Pharmaceuticals Inc (ENTA) has a Forward Free Cash Flow (FCF) yield of approximately -7.73%. Compared to its 3-year average FCF yield of -39.92%, the current FCF yield is approximately -80.64% lower. Relative to its 5-year average FCF yield of -26.08%, the current FCF yield is about -70.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ENTA competitors is 21.80, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA.O) exhibits a P/S ratio of 6.43, which is -70.51% above the industry average. Given its robust revenue growth of 9.76%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ENTA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ENTA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ENTA currently overvalued or undervalued?

Enanta Pharmaceuticals Inc (ENTA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of 1.28. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 15.12 to 31.56 according to relative valuation method. Compared to the current price of 14.51 USD, Enanta Pharmaceuticals Inc is Undervalued By 4.04%.

What is Enanta Pharmaceuticals Inc (ENTA) fair value?

ENTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between 15.12 to 31.56 according to relative valuation method.

How does ENTA's valuation metrics compare to the industry average?

The average P/S ratio for ENTA's competitors is 21.80, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA) exhibits a P/S ratio of 6.43, which is -70.51% above the industry average. Given its robust revenue growth of 9.76%, this premium appears unsustainable.

What is the current P/B ratio for Enanta Pharmaceuticals Inc (ENTA) as of Mar 03 2026?

As of Mar 03 2026, Enanta Pharmaceuticals Inc (ENTA) has a P/B ratio of 4.77. This indicates that the market values ENTA at 4.77 times its book value.

What is the current FCF Yield for Enanta Pharmaceuticals Inc (ENTA) as of Mar 03 2026?

As of Mar 03 2026, Enanta Pharmaceuticals Inc (ENTA) has a FCF Yield of -7.73%. This means that for every dollar of Enanta Pharmaceuticals Inc's market capitalization, the company generates -7.73 cents in free cash flow.

What is the current Forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA) as of Mar 03 2026?

As of Mar 03 2026, Enanta Pharmaceuticals Inc (ENTA) has a Forward P/E ratio of -4.70. This means the market is willing to pay $-4.70 for every dollar of Enanta Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Enanta Pharmaceuticals Inc (ENTA) as of Mar 03 2026?

As of Mar 03 2026, Enanta Pharmaceuticals Inc (ENTA) has a Forward P/S ratio of 6.43. This means the market is valuing ENTA at $6.43 for every dollar of expected revenue over the next 12 months.

ENTA Valuation